Skip to main content
Oncopeptides logo

Oncopeptides — Investor Relations & Filings

Ticker · ONCO ISIN · SE0009414576 LEI · 549300J9WWQ5CBYQ1M77 ST Manufacturing
Open in API
Filings indexed 483 across all filing types
Latest filing 2022-01-21 Legal Proceedings Report
Country SE Sweden
Listing ST ONCO

About Oncopeptides

https://www.oncopeptides.com/en

Oncopeptides is a biotechnology company focused on the research, development, and commercialization of targeted therapies for difficult-to-treat cancers. The company concentrates on hematological diseases, with a primary focus on multiple myeloma. Its commercialized product is Pepaxti (melflufen), a peptide-drug conjugate for adult patients with relapsed or refractory multiple myeloma. Founded in 2000 based on research from leading cancer institutions, Oncopeptides leverages its proprietary technology platforms to advance a pipeline of innovative drug candidates. The company's research also includes the development of Natural Killer (NK) cell engagers to address unmet medical needs in oncology.

Recent filings

Filing Released Lang Actions
Oncopeptides återkallar frivilliga tillbakadragandet av Pepaxto i USA – ingen avsikt att marknadsföra i USA i nuläget
Legal Proceedings Report Classification · 1% confidence The document is a press release dated January 21, 2022, from Oncopeptides AB, written in Swedish. The core content announces that the company has contacted the FDA to withdraw its previous request for voluntary withdrawal of Pepaxto in the USA, following further data analysis. It also mentions that the company has ceased marketing the product in the US for now and is engaging in dialogue with the FDA. This type of announcement, concerning regulatory interaction, product status changes, and market strategy shifts, is a significant corporate event announcement. It is not a full financial report (10-K or IR), an earnings release (ER), or a transcript (CT). Since it details a major regulatory/product status change and is issued as a formal press release, it fits best under the general 'Regulatory Filings' (RNS) category, as it is a mandatory public disclosure under EU market abuse regulation, or potentially a general announcement that doesn't fit the highly specific categories like DIV, NAV, or DIRS. Given the nature of the announcement (a formal communication about regulatory status and future marketing intent), RNS is the most appropriate general regulatory disclosure category.
2022-01-21 Swedish
Oncopeptides offentliggör kassalikviditeten per den 31 december 2021
Regulatory Filings Classification · 1% confidence The document is titled "Stockholm Pressmeddelande" (Stockholm Press Release) dated January 5, 2022, and its main subject is "Oncopeptides offentliggör kassalikviditeten per den 31 december 2021" (Oncopeptides publishes cash position as of December 31, 2021). It provides preliminary cash figures (360 MSEK) and operational spending estimates for 2022, explicitly stating that the formal reporting of liquidity will occur later with the publication of the year-end report on February 17, 2022. Since this is a brief announcement providing key financial highlights (preliminary cash position) ahead of a formal report, it fits the definition of an Earnings Release (ER). The document length (3370 chars) is short, supporting the idea that it is an announcement rather than the full report.
2022-01-05 Swedish
Oncopeptides announces year-end cash 2021
Earnings Release Classification · 1% confidence The document is a press release dated January 5, 2022, titled "Oncopeptides announces year-end cash 2021". It provides preliminary financial figures (cash position) and operational updates (cost reduction, burn rate) for the period ending 2021. Crucially, it explicitly states: "The cash position at year-end 2021 was approximately SEK 360 M. This figure is preliminary, and the formal reporting of the cash position will be part of the year-end report 2021, to be released on February 17, 2022." Because this document is an announcement providing key highlights and explicitly deferring the formal, comprehensive report to a later date (February 17, 2022), it fits the definition of an Earnings Release (ER), which covers initial announcements of periodical financial results (key highlights only). It is not the full Annual Report (10-K) or the comprehensive Interim Report (IR). FY 2021
2022-01-05 English
Interim / Quarterly Report 2021
Interim / Quarterly Report Classification · 1% confidence The document is titled 'DELÅRSRAPPORT Q3 2021' (Interim Report Q3 2021) and contains comprehensive financial statements, including income statements, cash flow summaries, and detailed management commentary on business performance, clinical trials (OCEAN/PORT studies), and strategic outlook. It is a substantive financial report for a period shorter than a full fiscal year, not merely an announcement or certification. Q3 2021
2021-11-24 Swedish
Interim / Quarterly Report 2021
Interim / Quarterly Report Classification · 1% confidence The document is titled 'INTERIM REPORT Q3 2021' and contains comprehensive financial statements, including a 'Financial overview of the group' table with comparative data for the period ending September 30, 2021. It also includes detailed management commentary on business operations, clinical trial results, and strategic outlook. As it provides substantive financial data for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. Q3 2021
2021-11-24 English
Major Shareholding Notification 2021
Major Shareholding Notification Classification · 1% confidence The document details a change in shareholding percentage by a specific holder (Avanza Bank Holding AB for Försäkringsaktiebolaget Avanza Pension). It explicitly mentions 'Reason for major shareholding notification Sell' and provides the resulting distribution of total holdings, including the new percentage (4.94509%) and number of shares (3,723,246). This structure perfectly matches the definition of a Major Shareholding Notification, which is classified as 'MRQ' in the provided schema. The document is a direct notification of a change in significant ownership, not an announcement of a report (RPA) or a general regulatory filing (RNS).
2021-11-16 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.